Business
XOMA Royalty Enters into Agreement to Acquire Generation Bio
- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna - - Generation Bio’s cell-targeted lipid nanoparticles (ctLNP) delivery platform for small interfering RNA (siRNA) and other nucleic acid therapies to be included in XOMA Royalty’s portfolio - EMERYVILLE, Calif. and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA), the biotech royalty aggregator, announced
About this update from Xoma Royalty Corporation
[{"type":"text","content":"- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna -","length":133,"tagName":"p"},{"type":"text","content":"- Generation Bio’s cell-targeted lipid nanoparticles (ctLNP) delivery platform for small interfering RNA (siRNA) and other nucleic acid therapies to be included in XOMA Royalty’s portfolio -","length":190,"tagName":"p"},{"type":"text","content":"EMERYVILLE, Calif. and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has entered into an agreement to acquire Generation Bio Co. (“Generation Bio”) (NASDAQ: GBIO) for a cash price of $4.2913 per share at the closing of the merger. Generation Bio stockholders also will receive one non-transferable contingent value right (“CVR”) per share that entitles holders to receive potential payments of a pro rata portion of:","length":531,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"100% of the amount by which net cash at closing, as finally determined pursuant to the CVR agreement, exceeds $29 million;","length":122,"tagName":"p"}]},{"val":[{"type":"text","content":"either 90% or 100% of any savings realized by XOMA Royalty on the Company’s Cambridge office lease obligations, subject to the timing of resolution of the lease obligations;","length":173,"tagName":"p"}]},{"val":[{"type":"text","content":"a share of any proceeds from Generation Bio’s existing license agreement with Moderna, which includes potential development and commercial milestones and royalties on commercial sales, calculated on a sliding scale delivering up to 90% of such payments to CVR holders; and","length":272,"tagName":"p"}]},{"val":[{"type":"text","content":"a share of payments from any out license or sale of the Generation Bio ctLNP delivery platform, calculated on a sliding scale delivering up to 70% of such payments to CVR holders","length":178,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":745,"olType":false},{"type":"text","content":"following the closing.","length":22,"tagName":"p"},{"type":"text","content":"Following a thorough review process conducted with the assistance of its legal and financial advisors, Generation Bio’s board of directors has determined that the acquisitio...